# Columbia Scientists Uncover Surprising Link Between Serotonin and Heart Valve Disease

Research reveals reduced serotonin transporter activity may accelerate degenerative mitral valve regurgitation.

- **Source:** [Latest Science News -- ScienceDaily](https://brifing.si/source/0eef8637-6c5b-4e79-8f5b-6c9c6b36cf16)
- **Published:** 2026-07-12
- **Topic:** [Data & AI](https://brifing.si/c/data-ai)
- **Original article:** <https://www.sciencedaily.com/releases/2026/07/260711010131.htm>
- **On Brifing:** https://brifing.si/s/fb1dfbf3-0b9e-4024-a93b-d02fc63a3f66

## An Unexpected Discovery

Columbia University's 2023 study revealed that serotonin, commonly associated with mood and digestion, may play a role in mitral valve degeneration. The research showed reduced serotonin transporter activity could accelerate mitral regurgitation progression.

## Why the Mitral Valve Matters

Located between the heart's left chambers, the mitral valve prevents blood backflow. In degenerative mitral regurgitation (DMR), valve deterioration causes leakage, reducing heart efficiency and potentially leading to heart failure over time.

## Analysis of 9,000 Patient Records

Researchers examined clinical data from over 9,000 DMR surgery patients. SSRI antidepressant users required surgery at younger ages, suggesting serotonin mechanisms might affect valve integrity in compromised hearts.

## Evidence from Mouse Models

Mice lacking the SERT gene developed thickened mitral valves. Normal mice given high-dose SSRIs showed similar changes, demonstrating a direct relationship between serotonin transporter activity and valve structure.

## Genetic Susceptibility Factor

The 'long' variant in the 5-HTTLPR gene region correlated with lower SERT activity. DMR patients with two copies required surgery more frequently, potentially explaining individual susceptibility to valve disease progression.

## SSRIs' Potential Impact

While SSRIs increase serotonin availability by inhibiting reuptake, this study provides first evidence this mechanism might accelerate structural changes in already damaged valves, warranting caution in prescription practices.

## Clinical Practice Implications

The findings suggest risk assessment before prescribing SSRIs to DMR patients, particularly those with genetic susceptibility. Alternative treatments might be considered, though more research is needed to establish causation.

## Illuminating Molecular Mechanisms

Lab experiments showed low SERT activity triggers abnormal cell proliferation and fibrous tissue accumulation in valve tissue, leading to structural deterioration and functional impairment over time.

## Multicenter Collaboration

The joint effort by Columbia, CHOP, and UPenn highlights interdisciplinary research value. Supported by NHLBI, this project successfully bridged basic science with clinical observations.

## Disease Management Implications

These discoveries could help identify new therapeutic targets for mitral regurgitation. Future treatments might focus on regulating serotonin signaling pathways to slow valve degeneration.

## Intersection of Cardiology and Neuroscience

This study reveals unexpected connections between cardiovascular and neurotransmitter systems traditionally viewed separately. The discovery opens new avenues for understanding complex inter-system interactions in human physiology.

## Sources covering this story

- https://www.sciencedaily.com/releases/2026/07/260711010131.htm — 

---

_Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._